Uroosa Ibrahim

Uroosa Ibrahim

Auto-generated profile, based on publicly available information

Uroosa Ibrahim

Department of Hematology-Oncology, Tisch Cancer Institute, Icahn School of Medicine at Mount Sinai, New York, NY

Research Focus & Metrics

Academic Career Length

13Years (2014-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
14 August 2020 in Leukemia
Verified
Journal Article
Closed access
PDF file
AVAnkur Varma
Ankur Varma
SKSatyajit Kosuri
Satyajit Kosuri
CUCelalettin Ustun
Celalettin Ustun
UIUroosa Ibrahim
Uroosa Ibrahim
JMJonathan Moreira
Jonathan Moreira
KAKehinde U. A. Adekola
Kehinde U. A. Adekola

18 November 2016 in Expert Review of Anticancer Therapy
Verified
Journal Article
Closed access
GVGautam Kishore Valecha
Gautam Kishore Valecha
AVAdarsh Vennepureddy
Adarsh Vennepureddy
UIUroosa Ibrahim
Uroosa Ibrahim
FSFiras Safa
Firas Safa
BSBachar Samra
Bachar Samra
JAJean Paul Atallah
Jean Paul Atallah
Introduction: Advanced non-small cell lung cancer (NSCLC) has been conventionally treated with cytotoxic chemotherapy with short-lived responses and significant toxicities. Monoclonal antibodies to programmed death-1 receptor (PD-1) and programmed death ligand 1 (PD-L1) have shown tremendous promise in the treatment of advanced NSCLC in various clinical trials. Areas covered: In this article, we will review the outcomes of various trials of anti-PD-1/anti-PD-L1 antibodies in the treatment of NSCLC. We will also discuss their mechanism of action and toxicities. Expert commentary: Anti-PD-1/PD-L1 antibodies offer several advantages including significant antitumor activity, induction of long lasting responses, and favorable safety profile. Several trials are now being conducted to evaluate their efficacy as first line agents as well as in combination with other agents. More research is also needed to identify other biomarkers, in addition to PD-L1 expression, that could more reliably predict response to these drugs, and aid in better patient selection.

1 June 2017 in Lung Cancer
Verified
Journal Article
Closed access
UIUroosa Ibrahim
Uroosa Ibrahim
ASAmina Saqib
Amina Saqib
JAJean Paul Atallah
Jean Paul Atallah

29 December 2017 in CASE
Verified
Journal Article
Open access
PDF file
NNNikhil Nalluri
Nikhil Nalluri
DADeepak Asti
Deepak Asti
VAViswajit Reddy Anugu
Viswajit Reddy Anugu
UIUroosa Ibrahim
Uroosa Ibrahim
JLJames C. Lafferty
James C. Lafferty
YOYefim Olkovsky
Yefim Olkovsky
• Echocardiography is used to diagnose hypertrophic obstructive cardiomyopathy (HOCM) and Takotsubo cardiomyopathy (TCM). • Hypotension in a patient with TCM should be evaluated for left ventricular outflow tract obstruction (LVOTO). • Management of TCM is challenging in patients with HOCM with severe LVOTO. • Hypotension in LVOTO may paradoxically worsen with standard intravenous inotropes. • Fluid resuscitation, beta-blockers, alpha agonists, and intra-aortic balloon pump are the treatment options in LVOTO.

1 March 2017 in Heart & Lung
Verified
Journal Article
Closed access
ASAmina Saqib
Amina Saqib
UIUroosa Ibrahim
Uroosa Ibrahim
PPParshva Patel
Parshva Patel
AJAbhyudaya Joshi
Abhyudaya Joshi
MCMichel Chalhoub
Michel Chalhoub

21 November 2017 in Cureus
Verified
Journal Article
Open access
PDF file
UIUroosa Ibrahim
Uroosa Ibrahim
ASAmina Saqib
Amina Saqib
FMFarhan Mohammad
Farhan Mohammad
JDJuan Ding
Juan Ding
BSBlerina Salman
Blerina Salman
MDMeekoo Dhar
Meekoo Dhar
Embryonal rhabdomyosarcoma (RMS) is a rare type of sarcoma, primarily seen in the pediatric and adolescent population. Three subtypes of embryonal RMS are described, with the botryoid type being the most common. The incidence of this disease in adult females is 0.4% to 1% with the affected age group being patients in the third to fourth decade of life. It is exceedingly rare in patients above 40 years of age. We describe the case of a 48-year-old female, gravida 9 para 5, who presented with abnormal vaginal bleeding and an exophytic mass on examination. Given her lack of requirement of maintaining parity, she underwent radical surgery. The tumor was 8 cm in the largest dimension with a high histologic grade and some cartilaginous differentiation. Immunohistochemical stains were positive for vimentin, CD99, myogenin, and MyoD1 consistent with a diagnosis of embryonal rhabdomyosarcoma, botryoid subtype. Based on high survival rates when treated with aggressive adjuvant chemotherapy, a decision was made to treat the patient with the ARST0331 regimen. We discuss the diagnostic pathologic features of the disease, the epidemiology, and the most common presentation along with prognostic factors, treatment strategies, and outcomes.